Julien Brillault

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9195775/publications.pdf

Version: 2024-02-01

20 papers

1,725 citations

567281 15 h-index 752698 20 g-index

20 all docs

20 docs citations

20 times ranked 1692 citing authors

#	Article	IF	CITATIONS
1	Aerosol Therapy with Colistin Methanesulfonate: a Biopharmaceutical Issue Illustrated in Rats. Antimicrobial Agents and Chemotherapy, 2010, 54, 3702-3707.	3.2	587
2	VEGF-Induced BBB Permeability is Associated with an MMP-9 Activity Increase in Cerebral ischemia: Both Effects Decreased by ANG-1. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 1491-1504.	4.3	172
3	Tissue-Type Plasminogen Activator Crosses the Intact Blood-Brain Barrier by Low-Density Lipoprotein Receptor–Related Protein-Mediated Transcytosis. Circulation, 2005, 111, 2241-2249.	1.6	166
4	Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharmaceutical Research, 2002, 19, 976-981.	3.5	150
5	Oxygen Glucose Deprivation Switches the Transport of tPA Across the Blood–Brain Barrier From an LRP-Dependent to an Increased LRP-Independent Process. Stroke, 2005, 36, 1059-1064.	2.0	110
6	Formulation of rifampicin–cyclodextrin complexes for lung nebulization. Journal of Controlled Release, 2008, 129, 93-99.	9.9	84
7	Moderate-to-severe ischemic conditions increase activity and phosphorylation of the cerebral microvascular endothelial cell Na+-K+-Clâ^' cotransporter. American Journal of Physiology - Cell Physiology, 2005, 289, C1492-C1501.	4.6	75
8	Intercommunications between brain capillary endothelial cells and glial cells increase the transcellular permeability of the blood-brain barrier during ischaemia. Journal of Neurochemistry, 2002, 83, 807-817.	3.9	73
9	P-Glycoprotein-Mediated Transport of Moxifloxacin in a Calu-3 Lung Epithelial Cell Model. Antimicrobial Agents and Chemotherapy, 2009, 53, 1457-1462.	3.2	55
10	Hypoxia effects on cell volume and ion uptake of cerebral microvascular endothelial cells. American Journal of Physiology - Cell Physiology, 2008, 294, C88-C96.	4.6	54
11	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 3. Tobramycin. Antimicrobial Agents and Chemotherapy, 2015, 59, 6646-6647.	3.2	44
12	Relative Contributions of Active Mediated Transport and Passive Diffusion of Fluoroquinolones with Various Lipophilicities in a Calu-3 Lung Epithelial Cell Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 543-545.	3.2	35
13	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 1. Ciprofloxacin, Moxifloxacin, and Grepafloxacin. Antimicrobial Agents and Chemotherapy, 2014, 58, 3942-3949.	3.2	33
14	Ciprofloxacin-Loaded Inorganic–Organic Composite Microparticles To Treat Bacterial Lung Infection. Molecular Pharmaceutics, 2016, 13, 100-112.	4.6	30
15	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam. Antimicrobial Agents and Chemotherapy, 2016, 60, 3196-3198.	3.2	17
16	Sustained-release microparticle dry powders of chloramphenicol palmitate or thiamphenicol palmitate prodrugs for lung delivery as aerosols. European Journal of Pharmaceutical Sciences, 2019, 138, 105028.	4.0	13
17	Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones. Pharmaceutics, 2020, 12, 387.	4.5	12
18	Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. Journal of Pharmaceutical Sciences, 2018, 107, 1178-1184.	3.3	8

#	Article	IF	CITATIONS
19	Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery. Pharmaceutics, 2020, 12, 557.	4.5	6
20	Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	1